Results 51 to 60 of about 181,406 (245)
The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci +25 more
wiley +1 more source
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner +52 more
wiley +1 more source
Hepatitis-associated aplastic anemia from workout supplement: Rare but potentially fatal entity
Hepatitis-associated aplastic anemia (HAAA) is a rare clinical syndrome characterized by bone marrow failure 1–3 months after development of hepatitis. Untreated, hepatitis-associated aplastic anemia has poor outcome and the mainstay of treatment remains
Sanjog Bastola +3 more
doaj +1 more source
Response of Paroxysmal Nocturnal Hemoglobinuria Clone with Aplastic Anemia to Rituximab
Paroxysmal nocturnal hemoglobinuria is caused by expansion of a hematopoietic stem cell clone with an acquired somatic mutation in the PIG-A gene. This mutation aborts the synthesis and expression of the glycosylphosphatidylinositol anchor proteins CD55
Radha Raghupathy, Olga Derman
doaj +1 more source
Background Very severe aplastic anemia is characterized by a hypoplastic bone marrow due to destruction of CD34+ stem cells by autoreactive T cells. Investigation of the pathomechanism by patient-specific gene expression analysis of the attacked stem ...
Ute Fischer +11 more
doaj +1 more source
Therapy for Aplastic Anemia [PDF]
Abstract A 24-year-old man from Ecuador presents to your clinic with dyspnea on exertion, bruising, and petechiae. He is noted to be pancytopenic with ANC 430, hemoglobin 7.4 g/dL (reticulocyte count 0.9%), and platelets 18 000. His BM biopsy is hypocellular for age. Ultimately, he is diagnosed with severe aplastic anemia. He is the only
Amy E, DeZern, Eva C, Guinan
openaire +2 more sources
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
Eltrombopag for the treatment of aplastic anemia: current perspectives [PDF]
Su Han Lum, John D GraingerDepartment of Blood and Marrow Transplant, Royal Manchester Children’s Hospital, Manchester, UK Abstract: Aplastic anemia (AA) is a potential life-threatening hematopoietic stem cell (HSC) disorder resulting in cytopenia.
Lum SH, Grainger JD
core
Standard front-line treatment for acquired aplastic anemia (AA) for patients is either immunosuppressive therapy (IST) or bone marrow transplantation (BMT), usually from an HLA identical sibling.
Sica, Simona +2 more
core +1 more source
This assay enables multiplex genotyping of HLA‐CREGs and HPA alleles from whole blood using qPCR with an integrated parallel negative control. Results are interpreted based on amplification curves and Ct values, with validity dependent on strict quality control criteria for both the target reactions and the negative control.
Huimin Ji +9 more
wiley +1 more source

